2.09

0.48% 0.010

After Hours: 2.08 -0.010 -0.48%

Chemomab Therapeutics Ltd Adr (CMMB)

Overview News Price History Financials Discussions Forecast

Chemomab Therapeutics Ltd Adr stock is traded at $2.09, with a volume of 51,719. It is up +0.48% in the last 24 hours and down -14.34% over the past month. Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Previous Close:

$2.08

Open:

$2.06

24h Volume:

51,719

Relative Volume:

0.50

Market Cap:

$39.41M

Revenue:

Net Income/Loss:

$-33.08M

P/E Ratio:

-0.7109

EPS:

-2.94

Net Cash Flow:

$-25.68M

1W Performance:

+2.45%

1M Performance:

-14.34%

6M Performance:

+100.96%

1Y Performance:

+237.10%

1-Day Range:

$2.03

$2.1238

1-Week Range:

$1.99

$2.19

52-Week Range:

$0.551

$2.55

Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile

Name

Chemomab Therapeutics Ltd Adr

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

972-77-331-0156

Address

KIRYAT ATIDIM, BUILDING 7, TEL AVIV

Employee

Twitter

Next Earnings Date

2024-11-14

Latest SEC Filings

CMMB's Discussions on Twitter

Compare CMMB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMMB Chemomab Therapeutics Ltd Adr	2.09	39.41M	0	-33.08M	-25.68M	-2.94
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-13-24	Initiated	Maxim Group	Buy
May-06-24	Upgrade	Oppenheimer	Perform → Outperform
Dec-19-23	Resumed	ROTH MKM	Buy

Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News

Jan 09, 2025

LogicMark Inc (LGMK) Recovers 0.71% From Low: Are We There Yet? - Stocks Register

Jan 09, 2025

Nov 19, 2024

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.

Nov 19, 2024

Nov 14, 2024

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com

Nov 14, 2024

Oct 15, 2024

Chemomab reports progress in PSC treatment trial - Investing.com

Oct 15, 2024

Sep 20, 2024

Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN

Sep 20, 2024

Sep 16, 2024

The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News

Sep 16, 2024

Sep 13, 2024

Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex

Sep 13, 2024

Sep 09, 2024